Oxidation of low density lipoproteins from patients with renal failure or renal transplants  by Sutherland, Wayne H.F. et al.
Kidney International, Vol. 48 (1995), pp. 227—236
Oxidation of low density lipoproteins from patients with renal
failure or renal transplants
WAYNE H.F. SUTHERLAND, ROBERT J. WALKER, MADELEINE J. BALL, SYLVIA A. STAPLEY,
and M. CLARE ROBERTSON
Department of Medicine, University of Otago Medical School, Dunedin, New Zealand
Oxidation of low density lipoproteins from patients with renal failure or
a renal transplant. Peroxidation of low density lipoproteins (LDL) may be
involved in the development of atherosclerosis which is prevalent in
patients with chronic renal failure and renal transplant recipients. We
determined the copper ion catalyzed oxidation in vitro, vitamin E content,
and chemical and fatty acid composition of LDL isolated from 38 patients
with renal disease and 15 healthy subjects. Also the acute effect of
hemodialysis treatment on LDL oxidation variables was tested. The lag
time in conjugated diene formation during oxidation was significantly (P =
0.011) shorter in LDL from renal transplant recipients (66 mm, N = 18)
mainly due to significantly (P < 0.05) shorter times in women (47 mm, N
= 7), compared with healthy subjects (83 mm, N = 15), patients on
hemodialysis (91 mm, N 13) and patients treated by continuous
ambulatory peritoneal dialysis (CAPD) (82 mm, N = 7). The maximum
rate and the extent of LDL oxidation were significantly (P < 0.01) lower
in all patients with renal disease compared with healthy subjects. The
triglyceride content of LDL was significantly (P < 0.001) higher in women
with kidney grafts (7.3%) compared with levels in the corresponding men
(5.3%) and healthy women (5.0%), and was correlated significantly with
the lag time in LDL oxidation in renal transplant recipients (Spearmans r
=
—0.502, P = 0.034). The percentage oleic acid in LDL was significantly
higher (P = 0.002) and the percentage linoleic acid was significantly lower
(P 0.046) in patients with renal disease, and may largely account for
their lower rates and extent of LDL oxidation. Levels of the LDL
oxidation variables and organic lipid peroxide content of LDL were not
significantly different before and after hemodialysis and 24 hours later.
These results suggest that LDL from women with renal transplants may be
abnormally susceptible to oxidation possibly due to increased triglyceride
content.
Patients with chronic renal failure have a substantially in-
creased risk of death from cardiovascular disease compared with
age-matched individuals from the general population [1]. Further-
more, the risk of coronary heart disease (CHD) remains high in
patients treated by hemodialysis [21 and kidney grafting [3]. Thus
treatments to counteract uremia do not decrease and may even
increase CHD risk in patients with renal insufficiency. Factors
responsible for the development of atherosclerosis in chronic
renal failure are not well known. Potentially atherogenic patterns
of lipid abnormalities are seen in patients receiving maintenance
hemodialysis including hypertriglyceridemia, increased levels of
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very low density lipoproteins (VLDL) and intermediate density
lipoproteins (IDL), low levels of high density lipoproteins (HDL)
and enrichment of low density lipoproteins (LDL) with triglycer-
ides [4, 5]. In renal transplant recipients raised levels of plasma
triglycerides, cholesterol, VLDL and LDL have been noted [6].
Hypertension and glucose intolerance are also associated with
chronic renal failure and may contribute to the lipid abnormalities
and to the increased risk of CHD in affected individuals.
Recently, lipid peroxidation [7] and particularly the oxidative
modification of LDL [8] have been postulated as important
factors in the development of atherosclerosis. Increased levels of
lipid peroxides [7] and autoantibodies to oxidatively modified
LDL [9] are detected in patients with atherosclerotic disease.
Also, the susceptibility of LDL to oxidation in vitro has been
associated with the severity of coronary atherosclerosis in patients
with CHD undergoing angioplasty [10]. Studies indicating that
antioxidants are capable of retarding the development of athero-
sclerosis in animals [11, 12] further support a role for lipid
oxidation in the formation of arterial lesions. Oxidized LDL has
several properties which are potentially atherogenic. For example,
oxidatively modified LDL promotes accumulation of cholesteryl
esters in cultured macrophages [8] reminiscent of foam cell
formation which is a key step in the development of the athero-
sclerotic lesion. In addition oxidized LDL are cytotoxic [13] and
are an attractant for macrophages [14].
There is evidence that oxidative stress is increased in patients
with chronic renal failure. Raised levels of lipid peroxidation
products are found in plasma from uremic patients [15, 161 and
during hemodialysis [17], and activation of oxidative metabolism
in polymorphonuclear leukocytes by the dialysis membrane has
been observed [18]. These conditions could increase the suscep-
tibility of LDL to oxidation. Recent studies have reported in-
creased susceptibility to oxidation of LDL isolated from patients
with chronic renal failure treated by hemodialysis or Continuous
ambulatory peritoneal dialysis (CAPD) [19]. Reduced efficiency
of the antioxidant vitamin E in LDL was also detected and may
contribute to this increased susceptibility of hemodialyzed LDL to
oxidation [20]. The acute effect of hemodialysis on the oxidation
of isolated LDL was not tested. In renal transplant recipients,
treatment with cyclosporine can increase the susceptibility of
isolated LDL to oxidation if blood levels of the drug are high
enough [20]. However, other factors including LDL lipid and fatty
acid composition could influence oxidation of LDL from patients
with chronic renal failure or kidney transplants. Circulating LDL
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is triglyceride-enriched in patients with renal failure [4], and high
LDL triglyceride content is associated with increased susceptibil-
ity of LDL to oxidation in vitro [10]. Fatty acid composition also
influences the oxidation of isolated LDL with increased content of
polyunsaturated fatty acids enhancing the susceptibility of LDL to
oxidation and increased content of monounsaturates having the
opposite effect [21, 22]. Furthermore, altered dietary intake of
these fatty acids leads to predictable changes in the oxidation of
isolated LDL [22—24]. Renal failure is frequently associated with
changes in diet which could conceivably alter fatty acid composi-
tion and oxidation of LDL from these patients.
The aim of the present study was to compare the susceptibility
to oxidation and the lipid, fatty acid, lipoperoxide and vitamin E
content of LDL among renal transplant recipients, patients with
chronic renal failure treated by hemodialysis or CAPD and
healthy subjects. In addition, oxidation of LDL was measured
immediately before, at the end, and 24 hours after hemodialysis to
test the acute effect of this procedure on LDL oxidation. In this
study we have used the terms "susceptibility or resistance to
oxidation" to refer to the delay in onset of LDL oxidation (lag
time) and "oxidizability" for the maximum rate of oxidation.
Methods
Subjects
Thirty-eight patients with chronic renal failure or kidney trans-
plants (ages 19 to 78 years) were recruited from patients attending
the Otago Nephrology Unit. Patients with nephrotic syndrome
and patients receiving lipid-lowering therapy were excluded.
Thirteen patients were on hemodialysis, seven were treated by
CAPD and 18 were renal transplant recipients. The etiology of
renal failure in the patients was as follows: glomerulonephritis
(N = 22), reflux nephropathy (N = 5), hypertension (N = 4),
autosomal dominant polycystic kidney disease (N = 2), diabetes
mellitus (N = 2) and other causes (N = 3). Eight patients had
evidence of ischemic heart disease (IHD) which was diagnosed on
the basis of clinical symptoms and signs, along with ECG or
echocardiographic changes or both. None of these patients had
suffered an ischemic event. Eighteen patients were receiving
cardiovascular medications. Angiotensin converting enzyme
(ACE) inhibitors and/or dihydropyridine calcium channel antag-
onists were most frequently used to treat hypertension. Two
patients were taking a beta-blocking drug. Most of the dialysis
patients were taking calcium carbonate as a phosphate binder and
1-a-calcitriol supplementation. Two patients were receiving eryth-
ropoietin subcutaneously. Renal transplant recipients received
azathioprine and prednisone ("double therapy," N = 5) or both
these drugs and cyclosporine A ("triple therapy," N = 11) or
cyclosporine A and prednisone (N = 2) to prevent rejection of the
kidney graft. Patients treated by dialysis were either on home
hemodialysis or CAPD. Hemodialysis patients were dialyzing
three times weekly (12 to 18 hr/week) using cellulose acetate
hollow fiber dialyzers and acetate dialysate. The usual length of a
hemodialysis procedure was five hours. The Baxter Disconnect
system was used by CAPD patients. Dietary protein intake was
not restricted in any patient group and none of the patients was
taking antioxidant supplements. Hemodialysis patients were ad-
vised to restrict intake of potassium-rich foods and fluid where
necessary, but were not given any other dietary advice. Six patients
including including three hemodialysis, one CAPD and two renal
transplant recipients smoked; they were all men.
Fifteen healthy subjects (ages 31 to 52 years) were recruited
from staff of the Dunedin Public Hospital and University of
Otago. None was taking medication or antioxidant supplements
and none smoked.
The study was approved by the Ethics Committee of the Otago
Area Health Board and participants gave written and informed
consent.
Lipoprotein separation
Venous blood was taken after an overnight fast and was
collected in vacutainer tubes containing disodium EDTA (1.5
mg/mi). Blood was collected from hemodialysis patients immedi-
ately before a dialysis session, at the end of dialysis and at the 24
hour point. Plasma was separated by low-speed centrifugation at
4°C. Sequential ultracentrifugation (20 and 24 hr at 40,000 rpm in
a Beckman 50.3 Ti rotor at 4°C) of plasma at densities 1.019 g/ml
and 1.063 g/ml was used to separate LDL (d 1.019 to 1.063 g/ml)
and VLDL+IDL (d 1.019 g/ml) fractions. LDL was dialyzed
against phosphate buffered saline (PBS) pH 7.4 and then PS
containing EDTA (5 jtmol/1iter) overnight at 4°C. The lipoprotein
was stored in the dark at 4°C and was used within three days.
Protein in LDL was measured by the Lowry method [251. High
density iipoprotein cholesterol was measured in the supernatant
after precipitation of apoB-containing lipoproteins with dextran
sulphate/magnesium chloride [26]. Cholesterol and triglycerides
were measured in plasma and lipoprotein fractions using enzy-
matic kits and calibrator supplied by Boehringer Mannheim Ltd
(Germany). In addition free cholesterol and phosphoiipids were
measured in LDL using enzymatic kits (Boehringer Mannheim
Ltd). Plasma lipoprotein (a) was measured using a two-site
radioimmunoassay kit (Pharmacia). Whole blood and plasma
cyclosporine levels were measured in the laboratories of Dunedin
Public Hospital by fluorescent polarization immunoassay using a
commercial kit (Abbott TDX).
Oxidation of LDL
Copper ions were used to oxidize the isolated LDL, and the
formation of conjugated dienes was measured to monitor oxida-
tion. Conjugated diene formation was determined essentially as
described by Sattler and coworkers [27]. To a quartz cuvette was
added PBS (2 ml) which had been aerated for 15 minutes, an
aliquot of LDL solution containing 50 jxg LDL protein and 5
jxmol/liter EDTA in PBS to bring the total volume to 2.2 ml. After
the addition of 32 jd of 1 mmoi/liter copper sulfate the absorbance
at 234 nm was monitored at 10 minute intervals. Quantities of
conjugated dienes formed were calculated using the molar extinc-
tion coefficient (29500 liter/mol/cm) for conjugated dienes. The
lag time was obtained from the intersection of lines drawn
through absorbance values before oxidation started (lag phase)
and during the following rapid oxidation (propagation phase) of
LDL. The rate of conjugated diene formation during the propa-
gation phase and also the maximum level of dienes attained were
calculated.
Fatty acid composition
Heptadecanoic acid (20 jid ofa 1.15 mg/mi solution in toluene)
internal standard was added to an aliquot (0.2 ml) of LDL
solution (protein 0.3 to 0.9 g/liter). The mixture was extracted
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Table 1. Clinical characteristics and plasma lipids and lipoprotein concentrations in the subjects
Healthy
HDN13 CAPDN=7 RTN=18 subjectsN=15 ANOVAP
Clinical features
Age years 51 19 65 7°f"' 42 13C 43 7 0.001
Gender (M/F) 11/2 6/1 11/7 5/10
Body weight kg 67.2 12.3 71.1 5.2 71.3 14.5 69.4 12.0 NS
BMI kg/rn2 22.2 2.9 25.5 1.7 24.9 5.0 25.0 4.0 NS
Duration of 30 33 36 39 60 42 NS
treatment
months
Plasma creatinine 741 301 751 129 158 68"' ND <0.001
nol/liter
Plasma lipids and lipoproteins mmol/liter
Cholesterol 5.50 1.24 6.70 157ab 6.41 1.15°° 5.36 0.57
VLDL + IDL cholesterol 1.31 0.60° 1.77 1.20a 0.86 034cd 0.73 0.46
LDL cholesterol 2.94 0.89 3.38 1.07 3.49 0.87 2.78 0.54
HDL cholesterol 1.02 0.54°° 1.01 018d 1.62 0.48 1.39 0.36
Triglycerides 2.05 0.87 2.12 1.02 1.63 0.59 1.42 0.81
VLDL + IDL triglycerides 1.60 0.75 1.53 0.95 1.20 0.56 1.05 0.77
Lp(a) U/liter 489 455 569 479 237 309 266 273
0.01
0.001
NS
0.001
NS
NS
0.07°
Values are mean SD. Abbreviations are: HD, hemodialysis; CAPD, continuous ambulatory peritoneal dialysis; RT, renal transplants; ANOVA,
analysis of variance; Lp(a) lipoprotein (a); ND, not determined.
Significance P < 0.05 (Duncan's test: a vs. healthy subjects; b HD vs. CAPD; RT vs. HD; d CAPD vs. RT
C Significance calculated on log transformed data
twice with chloroform/methanol (2:1) according to the Folch
procedure [28]. The combined extracts were evaporated to dry-
ness under nitrogen, then redissolved in a small volume of
chloroform/methanol (2:1) and transferred quantitatively to a
Teflon screw-cap tube. The solvent was again evaporated under
nitrogen and toluene (1 ml) and 14% boron trifluoride/methanol
(2 ml) were added. The tube was securely capped then heated on
a boiling water bath for 90 minutes. At the end of this transes-
terification step, the tube was cooled, water (1 ml) was added and
the fatty acid methyl esters were extracted twice with hexane. The
hexane extracts were brought to dryness under a stream of
nitrogen, redissolved in a small volume of dichloromethane and
transferred to a small conical minivial. The solvent was evapo-
rated under nitrogen and the residue was redissolved in 50 ,td of
dichloromethane. A 3 .tl sample of this solution was injected onto
a Chromopack CP Sil88 capillary column (50 m X 0.22 mm) in a
Varian 3700 gas chromatograph with a split-ratio set at 1:10.
Helium (0.8 kg/cm2 column head pressure and flow rate 1.5
ml/min) was used as the carrier gas and the injector temperature
was 260°C and the FID detector temperature was 280°C. Column
temperature was programmed from 165°C to 210°C at 3°/mm.
Peak area was measured using a Spectra-Physics SP 4290 integra-
tor. The peak quantification was based on peak area comparison
with the internal standard and fatty acid composition was ex-
pressed in wt %. The concentrations of fatty acids in LDL
(nmol/mg protein) were also calculated but are not reported.
Lipid peroxides
Organic lipid peroxide levels were measured in LDL prior to
oxidation using the method of el-Sadaani and coworkers [29]
modified to minimise binding of iodine to LDL {30J. LDL
solutions were diluted to 0.30 g protein/liter with PBS containing
5 xmol/liter EDTA. Duplicate aliquots (100 pA) of the mixture
were immediately taken, and 50 pA EDTA solution (3.7 mmol/
liter) and 10 .tl BHT solution (0.4 mmol/liter in methanol) were
added. Next a volume (7 ILl) of aqueous iodine solution (1
mmol/liter) and 86 pA acetic acid solution (3%) was added to the
aliquots of LDL and to standards containing hydrogen peroxide
and a blank of distilled water. One milliliter of a commercial
iodide cholesterol color reagent (Merck Ltd) was added to all
tubes and after 30 minutes in the dark at room temperature, the
absorbance of the reaction mixture was read at 365 nm against the
blank.
Vitamin E content of LDL expressed in xmol!g LDL protein
was measured by high pressure liquid chromatography according
to the method of Bieri, Tolliver and Catiguiani [31].
Statistical analysis
Comparison of values among groups of subjects were made
using analysis of variances combined with Duncan's multiple
range test. Student's t-test was used for comparing values between
two groups of subjects. Pearson's product-moment correlation
coefficients were used to test for relationships between variables.
In one case, Spearman's rank correlation was used to reduce the
effect of an outlying value on the correlation. Partial correlation
analysis was used to test relationships between two variables while
a third variable was held constant. Two-tailed tests of significance
were used and a P value of less than 0.05 was considered to be
statistically significant.
Results
Clinical characteristics and plasma lipids and lipoprotein con-
centrations of the subjects are shown in Table 1. The CAPD
patients were significantly older than the healthy subjects and
other renal patients. Plasma creatinine concentration was lower in
renal transplant recipients compared with dialyzed patients with
renal failure due to a successfully functioning kidney graft.
Cholesterol concentration was significantly higher in plasma from
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Table 2. Chemical composition and vitamin E content of low density
lipoproteins in patients with renal disease
Healthy
HD
N=13
CAPD
N=7
RT
N=18 subjectsN=15
ANOVA
P
Protein % 26.5 4.0 24.0 1.3 24.3 1.3 24.8 1.1 0.045
FC % 7.5 0.9 8.5 07d 10.0 1.5 9.5 2.2 <0.001
CE % 40.1 4.9 41.6 2.4 41.3 3.1 42.2 2.6 NS
TG % 8.0 2.2 7.9 2.3 6.1 1.4 5.1 1.1 <0.001
PL % 17.9 2.0 18.1 0.5 18.3 2.1 18.4 1.2 NS
Lipid 44 9abc 25 5 23 7 24 8 <0.001
peroxides
nmol/mg
Vitamin E 5.3 1.5 5.5 2.6 3.9 15cd 4.2 1.4 0.05
nmol/mg
protein
Values are mean SD. Abbreviations are: HD, hemodialysis; CAPD,
continuous ambulatory peritoneal dialysis; RT, renal transplant; FC, free
cholesterol; CE, cholesteryl esters; TG, triglycerides; PL, phospholipids.
Significance P < 0.05 (Duncan's test): a vs. healthy subjects; h HD vs.
CAPD; c HD vs. RT; d CAPD vs. RT
CAPD patients and renal transplant recipients compared with
healthy controls and hemodialyzed patients whose values were
similar to those in the controls. Plasma VLDL+IDL cholesterol
levels were significantly higher in patients treated by dialysis
compared with levels in the healthy subjects and renal transplant
recipients. The concentration of plasma HDL cholesterol in
hemodialyzed patients was significantly lower than levels in
healthy subjects and renal transplant recipients. Patients treated
by CAPD had levels of HDL cholesterol which were similar to
those in hemodialyzed patients and were significantly lower than
levels in renal transplant recipients. Plasma Lp(a) concentration
tended to be higher but not significantly (ANDVAP = 0.07, using
log transformed data) in patients receiving dialysis.
The chemical composition and content of lipid peroxides and
vitamin E in LDL from the subjects are shown in Table 2. Patients
treated by hemodialysis or CAPD had significantly lower content
of free cholesterol and significantly higher content of triglycerides
in LDL compared with renal transplant recipients and healthy
subjects. The contents of protein and lipid peroxides were signif-
icantly higher in LDL from hemodialysis patients compared with
other subjects. The vitamin E content in LDL from renal trans-
plant recipients was significantly lower than levels in dialyzed
patients with chronic renal failure. The ratio cholesterol/protein in
LDL from hemodialysis patients (3.15 0.73 xmol/mg) was
significantly (ANOVA P = 0.008) lower compared with values
from other subjects (CAPD 3.57 0.36 jxmol/mg; renal transplant
recipients 3.68 0.21 jxmol/mg; healthy subjects 3.60 0.26
xmol/mg).
The fatty acid composition of LDL from patients with renal
disease and healthy subjects is shown in Table 3. Oleic acid (18:1)
content of LDL was significantly higher in all treatment categories
of patients with renal disease compared with healthy subjects.
Linoleic acid (18:2) content of LDL was significantly lower in
patients treated by CAPD and tended to be lower in hemodia-
lyzed patients compared with healthy subjects.
Table 4 summarizes data obtained from the oxidation of
isolated LDL by copper ions. The lag time in conjugated diene
formation was significantly shorter in renal transplant recipients
compared with healthy subjects and hemodialyzed patients. The
Table 3. Fatty acid composition of low density lipoproteins isolated
from patients with renal disease
Healthy
Fatty acid
wt%
HD
N=13
CAPD
N=7
RT
N=18 subjectsN=14a
ANOVA
p
16:0 18.3 2.6 18.0 1.9 16.1 2.6 16.9 2.6 NS
16:1 1.4 0.5 1.9 0.7 1.7 0.7 1.5 0.4 NS
18:0 10.6 1.5 8.8 1.2 9.0 2.5 9.6 1.7 NS
18:1 21.2 36b 23.8 05bc 20.6 2.6k' 18.2 1.9 0.002
18:2 n-6 33.8 5.7 31.1 68bc 36.2 4.8 37.4 4.0 0.046
18:3 n-3 1.7 0.5 1.9 1.0 1.7 0.6 1.9 0.5 NS
20:3 n-6 1.4 0.6 1.7 0.5 1.6 0.5 1.7 0.4 NS
20:4 n-6 5.5 1.9 6.5 1.8 6.8 1.6 6.4 1.6 NS
20:5 n-3 2.3 0.6 2.4 1.2 2.8 2.3 2.5 1.5 NS
22:5 n-3 1.0 0.9 0.7 0.8 1.2 1.0 1.6 1.5 NS
22:6 n-3 2.7 1.0 3.4 1.0 2.6 1.1 2.5 0.9 NS
CAPD,Values are mean SD. Abbreviations are: HD, hemodialysis;
continuous ambulatory peritoneal dialysis; RT, renal transplant.
aData for one subject are missing for technical reasons
Significance P < 0.05 (Duncan's test): b vs. healthy subjects; ' CAPD vs.
RT
rate of conjugated diene formation and the maximum quantity of
diene production were significantly lower in all categories of renal
patients compared with healthy subjects. When patients who were
receiving cardiovascular drugs including ACE inhibitors, calcium
channel blockers and /3-blockers were excluded essentially similar
findings were obtained. Also two-way analysis of variances by
treatment group and cardiovascular drug therapy showed that
there was no significant effect of cardiovascular drugs on LDL
oxidation variables. Mean (± SD) levels of the LDL oxidation
variables were not significantly different between renal transplant
recipients treated with azathioprine and prednisone (lag time 75
37 mm; rate 8.29 1.01 nmol/mg/min; concentration 620 51
nmol/mg; N = 5) and those treated with cyclosporine and
prednisone with or without azathioprine (lag time 62 27 mm;
rate 8.27 1.01 nmol/mglmin; concentration 586 67 nmol/mg;
N = 13). The mean (± SD) lag time was significantly (P < 0.05)
lower in LDL from hemodialysis patients who smoked (78 9
mm, N = 3) compared with the corresponding value in those who
did not smoke (95 11 mm, N = 10). The mean (± SD) lipid
peroxide content of LDL (smokers 48 13 nmol/mg; nonsmokers
42 8 nmol/mg) was not significantly different between these
groups of patients. Two of the renal transplant recipients, both
men, smoked, but excluding their data did not significantly affect
measures of LDL oxidation variables.
There was substantial individual variation in lag time in LDL
oxidation in renal transplant recipients (Fig. 1), and those with
shorter lag times outside the current range of values in healthy
subjects were mainly women. Table 5 summarizes LDL oxidation
and composition data in men and women treated by dialysis, with
renal transplants and in the group of healthy subjects. Women
with renal transplants had significantly shorter lag times in
conjugated diene formation, lower LDL cholesteryl ester content
and higher LDL triglyceride content compared with men with
kidney grafts. Also the triglyceride content of LDL from these
women was significantly (P < 0.001) higher than the correspond-
ing value in healthy women. A significantly (P = 0.047) higher
proportion of women with kidney grafts were treated with aza-
thioprine and prednisone (22%), and a lower proportion were
treated with cyclosporine in combination with prednisone and/or
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Table 4. Conjugated diene formation during copper ion catalyzed oxidation of low density lipoproteins isolated from plasma of patients with renal
disease
HD CAPD RT Healthy subjects ANOVA P
All subjects N = 13 N = 7 N = 18 N = 15
Lag time mm 91 13 82 15 66 29"° 83 17 0.011
Rate nmol/minlmg 7.44 1.56a 7•43 2.20a 8.28 1.12 9.44 1.64 0.005
Concentration nmol/mg
No cardiovascular drugs'
571 55
N = 5
562 95
N = 7
596 64
N = 8
671 86
N = 15
0.002
Lag time mm 86 6 82 15 58 290 83 17 0.023
Rate nmol/min/mg 7.46 2.12 7.43 2.20 8.20 1.40 9.44 1.64 0.052
Concentration nmollmg 581 66 562 95 591 80 671 86 0.024
Values are mean SD and apart from lag time, are expressed with respect to LDL protein.
Abbreviations are: HD, hemodialysis; CAPD, continuous ambulatory peritoneal dialysis; RT, renal transplant.
Significance P < 0.05 (Duncan's test): a vs. healthy subjects; b HD vs. CAPD; 'HD vs. RT.
d Patients receiving angiotensin converting enzyme inhibitors, calcium channel blocking agents and (3-blocking drugs were excluded.
E
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Fig. 1. Lag time in conjugated diene formation during copper ion oxidation
of low density lipoproteins isolated from renal transplant recipients (RT) and
healthy subjects. Men with renal transplants (0); women with renal
transplants (•); healthy men (is); healthy women (A).
azathioprine (17%) compared with men (6% and 56%, respec-
tively). Mean whole blood cyclosporine levels were 166 ng/ml
(range 62 to 256 ng/ml) in women and 212 nglml (range 125 to 398
nglml) in men. The corresponding mean plasma levels were 70
ng/ml (women) and 104 nglml (men). The lag time was lower in
women receiving triple therapy (27 11 mm, N = 3) compared
with those receiving double therapy (62 24 mm, N = 4) at a
marginal level of significance (P = 0.07). The content of triglyc-
erides in LDL was not significantly different between these two
groups of women. In men with renal transplants, the lag time was
not significantly different between those receiving triple therapy
(73 18 mm, N = 8) compared with those treated with double
therapy (88 14 mm, N = 3). The proportion of women with
renal transplants taking cardiovascular drugs (43%) was not
significantly different from the corresponding proportion of men
(36%). Also, age (men 44 14 years; women 40 12 years; mean
SD) and LDL content of oleic acid (men 20.5 2.7%; women
20.6 2.6%) were not significantly different between men and
women with renal transplants. In women treated by dialysis
(hemodialysis or CAPD), the lag time was significantly longer, the
maximum concentration of dienes produced was significantly less,
LDL triglyceride content was higher at a marginal level of
significance (P = 0.063) and LDL vitamin E content was signifi-
cantly higher compared with values in men receiving dialysis. The
content of oleic acid in LDL tended to be higher (women 24.4
3.2%; men 21.7 4.1%; mean SD) and the content of linoleic
acid tended to be lower (women 30.1 7.1%; men 33.3 6.0%;
mean SD) in women receiving dialysis, but these differences did
not attain statistical significance.
Table 6 shows the effect of hemodialysis on copper-catalyzed
oxidation of isolated LDL from 12 out of the 13 patients treated
by hemodialysis. None of the measured variables changed signif-
icantly during hemodialysis. Baseline lipid peroxide content of
LDL also did not change significantly during hemodialysis (im-
mediately before 45 8 nmol/mg; end 49 23 nmol/mg; 24 hr 46
6 nmol/mg; mean SD).
Since the patients with evidence of IHD were all dialysis-
dependent their characteristics were compared with those of the
remaining dialysis-dependent patients who had no evidence of
IHD, and these data are summarised in Table 7. The patients with
IHD were significantly older than those with no evidence of the
condition.
Correlation analysis
The lag time (r = 0.357, N = 52, P = 0.009), rate (r = —0.670,
N = 52, P < 0.001) and maximum concentration (r = —0.615,
N = 52, P < 0.001) of conjugated dienes formed were correlated
significantly with the oleic acid content of LDL in all subjects
combined (Fig. 2). The rate (r = 0.627, N = 52, P < 0.001) and
maximum concentration (r = 0.561, N = 52, P < 0.001) of dienes
formed were also correlated significantly with the linoleic acid
content of LDL (Fig. 3). The lag time was correlated significantly
with the triglyceride content of LDL in renal transplant recipients
(Fig. 4) but not in the other groups of subjects (hemodialysis: r =
—0.164; CAPD: r = 0.276; healthy subjects: r = —0.190). In those
who were receiving "triple therapy," the lag time was not corre-
lated significantly with the plasma concentration of cyclosporine
(r = 0.017, N = 13). The vitamin E concentration in LDL (r =
0.166) and the rate of diene formation (r = —0.117) were not
correlated significantly with the lag time in conjugated diene
formation (N = 53). The rate of conjugated diene formation (r =
—0.377, N = 53, P = 0.005) and the maximum concentration of
conjugated dienes formed (r = —0.403, N = 53, P = 0.003) were
correlated significantly with the LDL content of triglyceride. The
0
0
B.
S
I
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Table 5. Low density lipoprotein oxidation and composition in men and women with renal disease and in healthy subjects
Dialysis patients RT Healthy subjects
Men Women Men Women Men Women
N=17 N=3 N=11 N=7 N=6 N=9
Lag time mm 85 13 104 ioa 77 25 47 26 80 17 85 19
Rate nmol/min/mg 7.67 1.79 6.13 0.66 8.44 1.09 8.03 1.22 9.76 2.03 9.23 1.41
Concentration nmol/mg 581 64 492 45 599 57 590 78 699 104 653 73
Protein % 25.5 3.7 26.1 2.4 24.3 1.3 24.3 1.4 24.7 1.1 24.9 1.2
FC % 7.9 1.0 7.8 0.3 9.8 1.7 10.4 1.1 8.4 1.5 10.3 2.4
CE % 41.0 4.3 38.3 1.9 42.5 3.0 39.5 2.3a 43.7 0.8 41.2 2.9a
TG % 7.6 1.9 10.1 2.8 5.3 0.8 7•3 12h 5.2 1.4 5.0 0.9
PL % 18.0 1.8 17.8 0.1 18.5 2.7 18.4 2.5 18.0 1.3 18.7 1.1
Lipid peroxides nmol/mg 36 13 40 12 23 5 23 9 24 3 26 6
Vitamin E nmollmg 5.0 1.5 7.4 3.Oa 3.5 1.4 4.4 1.7 4.1 1.4 4.2 1.4
Values are mean SD. Abbreviations are: RT, renal transplant recipients; FC, free cholesterol; CE, cholesteryl esters; TG, triglycerides; PL,
phospholipids.
Significance of difference between mean values for men and women (Student's t-test): a P < 0.05; bP < 0.001
Table 6. Effect of hemodialysis therapy on conjugated diene formation
during copper ion catalyzed oxidation of low density lipoproteins from
patients with renal disease
States of hemodialysis ANOVA
PBeforea End 24 hr later
Lag time mm 90 12 88 32 86 29 NS
Rate nmol/mg/h 7.21 1.39 6.86 1.81 6.75 1.35 NS
Maximum nmol/mg 563 49 541 50 566 52 NS
Values are mean so, N = 12.
a "Before" is immediately prior to dialysis and "end" is immediately
after dialysis
content of triglycerides in LDL was also correlated significantly
with the corresponding content of oleic acid (r = 0.398, N = 52,
P = 0.004) and linoleic acid (r = —0.415, N = 52, P = 0.002).
When LDL content of oleic acid or linoleic acid was held constant
in partial correlation analysis, the rate of diene formation (oleic
acid r =
—0.162; linoleic acid r =
—0.165) and maximum
concentration of dienes produced (oleic acid r =
—0.218; linoleic
acid r =
—0.226) were no longer correlated significantly with LDL
triglycerides. The lag time was not correlated significantly with
duration of treatment in patients receiving hemodialysis (r =
—0.221) or CAPD (r = —0.130) and renal transplant recipients(r = 0.000).
Discussion
Oxidation of LDL is believed to be an important step in the
development of atherosclerosis [8]. Since atherosclerotic disease
is prevalent in patients with chronic renal failure or renal trans-
plants, we sought evidence that LDL from these patients is more
susceptible to oxidation in vitro. Our data show that lag times in
conjugated diene formation are abnormally short when LDL from
women with renal transplants are oxidized in vitro, suggesting that
the susceptibility of the lipoprotein to oxidation may be increased
in these women.
The inverse correlation between lag time and LDL triglyceride
content in the present renal transplant recipients suggests that the
short lag time in LDL oxidation in women with kidney grafts may
be due in part to the abnormally high content of triglycerides in
the lipoprotein. Triglyceride-enrichment of LDL has also been
associated with increased susceptibility to copper ion oxidation in
Table 7. Characteristics of patients with renal disease and ischemic
heart disease (IHD[+]) and patients undergoing similar therapy but
with no evidence of ischemic heart disease (IHD[—j)
IHD[+IaN=8 IHD[—]N=12 P
Clinical features
Age years 67 7 49 18 0.005
Body weight kg 68.7 8.8 68.5 11.7 NS
Duration of treatment months 17 12 43 40 0.052
Plasma creatinine onol/liter 688 169 782 293 NS
LDL oxidation
Lag time mm 91 12 86 15 NS
Rate nmol/min/mg 7.36 1.89 7.49 1.74 NS
Concentration nmol/mg 586 74 556 66 NS
Plasma lipids and
lipoproteins mmol/liter
Cholesterol 611 1.23 5.79 1.62 NS
VLDL + IDL cholesterol 1.30 0.64 1.59 0.99 NS
LDL cholesterol 3.45 0.99 2.86 0.89 NS
HDL cholesterol 1.12 0.40 0.95 0.47 NS
Triglycerides 1.76 0.86 2.29 0.90 NS
VLDL + IDL triglycerides 1.24 0.77 1.80 0.77 NS
Lp(a) U/liter 574 530 479 413 NSb
Values are mean SD. Abbreviations are: VLDL, very low density
lipoproteins; IDL, intermediate density lipoproteins; LDL, low density
lipoproteins; HDL, high density lipoproteins.
a Includes 4 patients treated by hemodialysis and 4 patients treated by
CAPD.
b Significance calculated on log transformed data
male survivors of myocardial infarction in a previous study [10].
The mechanism underlying this association is not clear. It is
possible that triglyceride-enrichment may alter the physicochem-
ical properties of LDL and thereby increase the susceptibility of
the lipoprotein to oxidation. In the present study, LDL from men
and women receiving dialysis treatment were also triglyceride-
enriched but lag times in LDL oxidation were not reduced. This
finding may be due to increased antioxidant protection as a result
of the higher content of vitamin E in LDL from these patients
compared with the renal transplant recipients. Vitamin E is the
most abundant antioxidant in LDL and raising the levels of this
antioxidant increases the lag time in LDL oxidation [32].
Cyclosporine at blood levels greater than 100 ng/ml is reported
as accelerating the oxidation of isolated LDL [20]. In the present
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Fig. 2. Correlation between low density lipoprotein (LDL) oleic acid (18:1)
content and lag time, rate and maximum concentration in conjugated diene
fonnation during copper ion oxidation of LDL isolated from patients with
chronic renalfailure or a renal transplant. Symbols are: (LI) hemodialysis (N
= 13); () CAPD (N 7); (+) renal transplant recipients (N = 18); (0)
healthy subjects (N = 14).
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Fig. 3. Correlation between low density lipoprotein linoleic acid content
(18:2) and rate and maximum concentration of conjugated dienes formed
during copper ion oxidation of LDL isolated from patients with chronic renal
failure or a renal transplant. Symbols are: (LI) hemodialysis (N = 13); ()
CAPD (N 7); (+) renal transplant recipients (N = 18); (0) healthy
subjects (N = 14).
study, LDL from women receiving triple therapy tended to be
particularly susceptible to oxidation, suggesting that cyclosporine
treatment may have contributed to the short lag time in LDL
oxidation in women with kidney grafts. However, plasma cyclo-
sporine levels were unrelated to LDL oxidation in renal transplant
recipients and cyclosporine treatment did not appear to have
greatly influenced the oxidation of LDL from men with kidney
grafts. They had lag times in LDL oxidation that were not clearly
30
18:2 (wt%)
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different from normal in spite of the fact that their blood
cyclosporine levels were higher than levels (100 ng/ml) reported as
stimulating LDL oxidation in vitro [20]. This apparent ineffective-
ness of cyclosporine treatment on LDL oxidation in men is
unexplained. Although captopril (an ACE inhibitor) and /3-block-
ing drugs are reported as reducing the susceptibility of isolated
LDL to oxidation [33, 34], there was no evidence in our data that
treatment with cardiovascular drugs had any appreciable influ-
ence on LDL oxidation in renal transplant recipients or in the
total group of renal patients.
In this study and in a previous report [21], the lag time in
conjugated diene formation was linked with LDL oleate content,
but this relationship did not appear to explain the abnormally
short lag times in oxidation of LDL from the present women with
renal transplants. Thus the fatty acid composition of LDL was
similar in men and women with kidney grafts while lag times were
markedly longer in the men. Once antioxidant protection was
depleted, the rate and extent of conjugated diene formation from
LDL isolated from renal patients, and more particularly those
treated by dialysis, were lower than values in healthy subjects. The
close correlations between these oxidation variables and LDL
content of oleic acid (inverse) and linoleic acid (positive) suggest
that lower LDL linoleate and higher LDL oleate content contrib-
uted to the lower rate and extent of conjugated diene formation in
LDL from dialysis patients. Similar relationships have been
reported previously in mildly hypercholesterolemic patients [22]
and a combined group of healthy subjects and vitamin E-deficient
individuals [21]. Furthermore, changes in LDL content of oleate
and linoleate by supplementing the diet with these fatty acids
produces the predicted changes in rate and extent of LDL
oxidation [22—24]. Usually a faster maximum rate accompanies a
shorter lag time in LDL oxidation, but in the present renal
transplant recipients the lag time was shorter and the rate of diene
formation was slower than normal. This apparent discrepancy may
be due to comparatively high LDL oleate content which is
associated with slower rates of diene formation.
In contrast to a recent report of increased susceptibility to
oxidation of LDL isolated from dialysis patients [19], LDL from
the corresponding patients in the present study was not abnor-
mally prone to oxidation. Whether or not these differing findings
are related to the shorter lag times in conjugated diene formation
in LDL from the dialysis patients and healthy subjects we studied
compared with those reported previously [19] is uncertain. Vita-
min E content of LDL was lower and may explain the shorter lag
times in our data. Also, the patients reported on by Maggi et al
[19] were from Italy where the diet is usually rich in olive oil, and
could therefore lead to LDL that is enriched in oleic acid and
particularly resistant to oxidation [22—24]. It seems unlikely that
oxidation of LDL during its separation from plasma is mainly
responsible for the shorter lag times we observed because EDTA
was present throughout the isolation procedure. Lipid peroxide
levels were abnormally high in LDL from the current hemodialysis
patients, but this finding has been documented previously [17].
There is evidence that enrichment with lipid peroxides increases
the susceptibility of LDL to oxidation by copper ions [35, 36].
However, in spite of increased lipid peroxide content hemodia-
lyzed LDL was not abnormally susceptible to oxidation in the
present study. It is possible that the higher vitamin E content and
lower cholesterol/protein ratio may have counteracted any pro-
oxidant effects of raised lipid peroxide levels in hemodialyzed
LDL. In support of this hypothesis, Frei and Gaziano [36] have
reported that a low cholesterol/protein ratio is associated with
increased resistance of LDL to oxidation by copper ions. In the
present study, the comparatively normal resistance of hemodia-
lyzed LDL to oxidation seems to be consistent with the finding
that acute hemodialysis did not alter the susceptibility of LDL to
oxidation, and the duration of hemodialysis treatment and the lag
time in LDL oxidation were unrelated. These variables were also
unrelated in the study reported by Maggi et al [19].
Acute smoking is reported as raising LDL lipid peroxide
content and increasing the susceptibility of the isolated lipopro-
tein to oxidation [37]. Accordingly, LDL from current hemodial-
ysis patients who smoked showed increased susceptibility to
oxidation, but this did not appear to be mediated by lipid peroxide
content of the lipoprotein which was similar in smokers and
nonsmokers. Overall, there were few smokers and smoking status
did not appreciably influence major findings on LDL oxidation in
this study.
We isolated plasma LDL between densities 1.019 g/ml and
1.063 g/ml and the lipoprotein fraction may therefore contain
varying quantities of Lp(a) that has a longer lag time than LDL
during copper ion oxidation [27]. It is unlikely that Lp(a) content
of the LDL fraction greatly influenced the lag times in diene
formation that we observed in renal patients, because lag times
were similar in CAPD patients and healthy controls despite higher
levels of plasma Lp(a) in the patients.
In the present study, the maximum rates of LDL oxidation
suggest that LDL from all patients with renal disease, and
particularly those receiving dialysis, may be less readily oxidized
than normal. In contrast, lag times in LDL oxidation suggest that
the susceptibility of the lipoprotein to oxidation is comparatively
normal in most patients with renal disease, excepting women with
renal transplants whose LDL is more prone to oxidation. This
inconsistency raises the question which index of LDL oxidation
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Fig. 4. Correlation between low density lipoprotein triglyceride content (LDL
TG) and lag time in conjugated diene formation during copper ion oxidation
of LDL isolated from renal transplant recipients. Symbols are: (S) men (N
= 11); (0) women (N = 7).Spearman's rank correlation coefficient for the
relationship is —0.502, P =0.034.
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should be given greater weight in assessing the potential of LDL
for oxidation in vivo. De Graaf and coworkers [38] have suggested
that more value should be given to the duration of the lag time in
conjugated diene formation because at the end of this period
there are alterations in LDL that could theoretically influence its
biological activity, Indeed, increased levels of minimally oxida-
tively modified LDL would be expected during or not long after
the end of the lag time, and these particles have potentially
atherogenic properties [39]. On the other hand, if an LDL particle
becomes trapped within the intimal matrix and subjected to
sustained oxidative stress, the rate and extent of LDL oxidation
may also be important in determining the subsequent likelihood
and degree of any atherosclerotic changes. Recent evidence
suggests that oxidation of LDL in vitro may not necessarily parallel
in vivo oxidation of the lipoprotein measured as circulating levels
of autoantibodies to oxidized LDL [40]. Increased levels of these
antibodies have been detected in patients receiving dialysis [41],
which seems to be at variance with our finding of normal
susceptibility to in vitro oxidation of LDL isolated from this
category of patients. Further studies comparing these measures of
LDL oxidation are required.
Regnstrom and coworkers have reported that the lag time in
LDL oxidation is correlated inversely with the severity of coronary
atherosclerosis in men with a first myocardial infarction [10].
However, the presence of subjects with evidence of IHD did not
appear to influence our findings, and values for LDL oxidation
variables were similar in dialysis dependent patients with chronic
renal failure with or without evidence of IHD, and none of the
women with renal transplants had clinically important cardiovas-
cular disease. A recent study has reported similar levels of
circulating autoantibodies to oxidized LDL, suggesting that rates
of LDL oxidation in vivo may also be similar in dialysis patients
with or without IHD [41]. It is possible that subclinical vascular
disease was present in patients without evidence of IHD, and that
there were differences in lifestyle that may have obscured any
difference in LDL oxidation associated with IHD. On the other
hand, it is also possible that LDL oxidation is not the predominant
risk factor for IHD in dialysis patients. The classical risk factors
including older age and higher plasma LDL cholesterol levels
tended to distinguish patients with evidence of IHD in our data.
There are limitations to the present findings. The main study
was cross sectional, and levels of variables prior to treatment for
kidney failure are unknown. The numbers of subjects in each
category of renal patients were comparatively small, increasing
the risk of a non-representative sample. On the other hand,
clinical findings and plasma lipid and lipoprotein levels in patients
in the treatment groups were essentially in agreement with
reported data [4—6]. The trend toward high levels of HDL
cholesterol in the renal transplant recipients we studied has been
noted in some [42], but not all studies [43, 44], and is possibly due
to immunosuppressive therapy and improved renal function [421.
In conclusion, this study has provided evidence that LDL from
women with renal transplants is abnormally susceptible to oxida-
tion in vitro, and we speculate that this may possibly increase their
risk of future atherosclerotic disease. Measurement of autoanti-
bodies against oxidized LDL is required to confirm that oxidation
of LDL in vivo may also be increased in these women.
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